mutLBSgeneDB |
Gene summary for MAP2K6 |
Gene summary |
Basic gene Info. | Gene symbol | MAP2K6 |
Gene name | mitogen-activated protein kinase kinase 6 | |
Synonyms | MAPKK6|MEK6|MKK6|PRKMK6|SAPKK-3|SAPKK3 | |
Cytomap | UCSC genome browser: 17q24.3 | |
Type of gene | protein-coding | |
RefGenes | NM_002758.3, NM_031988.1, | |
Description | MAPK/ERK kinase 6MAPKK 6MEK 6SAPK kinase 3dual specificity mitogen-activated protein kinase kinase 6protein kinase, mitogen-activated, kinase 6 (MAP kinase kinase 6)stress-activated protein kinase kinase 3 | |
Modification date | 20141222 | |
dbXrefs | MIM : 601254 | |
HGNC : HGNC | ||
HPRD : 03155 | ||
Protein | UniProt: P52564 go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_MAP2K6 | |
BioGPS: 5608 | ||
Pathway | NCI Pathway Interaction Database: MAP2K6 | |
KEGG: MAP2K6 | ||
REACTOME: MAP2K6 | ||
Pathway Commons: MAP2K6 | ||
Context | iHOP: MAP2K6 | |
ligand binding site mutation search in PubMed: MAP2K6 | ||
UCL Cancer Institute: MAP2K6 | ||
Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO Term | PubMed ID |
Top |
Ligand binding site mutations for MAP2K6 |
Cancer type specific mutLBS sorted by frequency |
LBS | AAchange of nsSNV | Cancer type | # samples | K82 | R83Q | UCEC | 2 | N184 | N184D | COAD | 1 | K210 | K210R | STAD | 1 | D197 | D197N | UCEC | 1 | K138 | K138T | UCEC | 1 |
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
Top |
Protein structure related information for MAP2K6 |
Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
: nsSNV at non-LBS: nsSNV at LBS |
nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
LBS | AAchange of nsSNV | Relative stability change | D197 | D197N | -1.3326661 | K138 | K138T | -0.72483593 | K210 | K210R | -0.65102835 | N184 | N184D | -0.64886155 | K82 | R83Q | -0.54731131 |
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
Structure image for MAP2K6 from PDB |
PDB ID | PDB title | PDB structure | 3VN9 | Rifined Crystal structure of non-phosphorylated MAP2K6 in a putative auto-inhibition state |
Top |
Differential gene expression and gene-gene network for MAP2K6 |
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
Top |
Top |
Phenotype information for MAP2K6 |
Gene level disease information (DisGeNet) |
Disease ID | Disease name | # PubMed | Association type |
umls:C0009375 | Colonic Neoplasms | 1 | Therapeutic |
Mutation level pathogenic information (ClinVar annotation) |
Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
Top |
Pharmacological information for MAP2K6 |
Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
Gene-centered drug-gene interaction network |
Drug information targeting mutLBSgene (Approved drugs only) |
Drug status | DrugBank ID | Name | Type | Drug structure |
Gene-centered ligand-gene interaction network |
Ligands binding to mutated ligand binding site of MAP2K6 go to BioLip |
Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | ANK | 9-{5-O-[(R)-HYDROXY{[(S)-HYDROXY(PHOSPHONOAMINO)PHOSPHORYL]OXY}PHOSPHORYL]-BETA-L-RIBOFURANOSYL}-9H-PURIN-6-AMINE | 3vn9 | A | K82 K138 N184 D197 K210 | MG | MAGNESIUM(2+) | 3vn9 | A | N184 D197 |
Top |
Conservation information for LBS of MAP2K6 |
Multiple alignments for P52564 in multiple species |
LBS | AA sequence | # species | Species | A63 | ELGRGAYGVVE | 3 | Homo sapiens, Mus musculus, Bos taurus | A63 | ELGKGGYGIVE | 1 | Caenorhabditis elegans | A80 | SGQIMAVKRIR | 2 | Homo sapiens, Mus musculus | A80 | SGIIMAVKRIK | 1 | Caenorhabditis elegans | A80 | SEQIMAVKRIR | 1 | Bos taurus | C196 | GQVKMCDFGIS | 3 | Homo sapiens, Mus musculus, Bos taurus | C196 | GQVKICDFGIS | 1 | Caenorhabditis elegans | D133 | CMELMDTSLDK | 3 | Homo sapiens, Mus musculus, Bos taurus | D133 | CMEVMDTSLDK | 1 | Caenorhabditis elegans | D137 | MDTSLDKFYKQ | 3 | Homo sapiens, Mus musculus, Bos taurus | D137 | MDTSLDKFYRH | 1 | Caenorhabditis elegans | D179 | SVIHRDVKPSN | 3 | Homo sapiens, Mus musculus, Bos taurus | D179 | NLIHRDVKPSN | 1 | Caenorhabditis elegans | D197 | QVKMCDFGISG | 3 | Homo sapiens, Mus musculus, Bos taurus | D197 | QVKICDFGISG | 1 | Caenorhabditis elegans | E130 | VWICMELMDTS | 3 | Homo sapiens, Mus musculus, Bos taurus | E130 | VWICMEVMDTS | 1 | Caenorhabditis elegans | G60 | PIVELGRGAYG | 2 | Mus musculus, Bos taurus | G60 | PIMELGRGAYG | 1 | Homo sapiens | G60 | VLEELGKGGYG | 1 | Caenorhabditis elegans | K138 | DTSLDKFYKQV | 3 | Homo sapiens, Mus musculus, Bos taurus | K138 | DTSLDKFYRHA | 1 | Caenorhabditis elegans | K181 | IHRDVKPSNVL | 3 | Homo sapiens, Mus musculus, Bos taurus | K181 | IHRDVKPSNIL | 1 | Caenorhabditis elegans | K210 | VDSVAKTIDAG | 3 | Homo sapiens, Mus musculus, Bos taurus | K210 | TNSMAKTVQAG | 1 | Caenorhabditis elegans | K82 | QIMAVKRIRAT | 3 | Homo sapiens, Mus musculus, Bos taurus | K82 | IIMAVKRIKSS | 1 | Caenorhabditis elegans | L131 | WICMELMDTSL | 3 | Homo sapiens, Mus musculus, Bos taurus | L131 | WICMEVMDTSL | 1 | Caenorhabditis elegans | L186 | KPSNVLINALG | 2 | Homo sapiens, Bos taurus | L186 | KPSNILLNRHG | 1 | Caenorhabditis elegans | L186 | KPSNVLINTLG | 1 | Mus musculus | L59 | EPIVELGRGAY | 2 | Mus musculus, Bos taurus | L59 | EPIMELGRGAY | 1 | Homo sapiens | L59 | VVLEELGKGGY | 1 | Caenorhabditis elegans | M129 | DVWICMELMDT | 3 | Homo sapiens, Mus musculus, Bos taurus | M129 | DVWICMEVMDT | 1 | Caenorhabditis elegans | M132 | ICMELMDTSLD | 3 | Homo sapiens, Mus musculus, Bos taurus | M132 | ICMEVMDTSLD | 1 | Caenorhabditis elegans | N184 | DVKPSNVLINA | 2 | Homo sapiens, Bos taurus | N184 | DVKPSNILLNR | 1 | Caenorhabditis elegans | N184 | DVKPSNVLINT | 1 | Mus musculus | S135 | ELMDTSLDKFY | 3 | Homo sapiens, Mus musculus, Bos taurus | S135 | EVMDTSLDKFY | 1 | Caenorhabditis elegans | S183 | RDVKPSNVLIN | 3 | Homo sapiens, Mus musculus, Bos taurus | S183 | RDVKPSNILLN | 1 | Caenorhabditis elegans | T134 | MELMDTSLDKF | 3 | Homo sapiens, Mus musculus, Bos taurus | T134 | MEVMDTSLDKF | 1 | Caenorhabditis elegans | V67 | GAYGVVEKMRH | 3 | Homo sapiens, Mus musculus, Bos taurus | V67 | GGYGIVEKMQH | 1 | Caenorhabditis elegans | Y64 | LGRGAYGVVEK | 3 | Homo sapiens, Mus musculus, Bos taurus | Y64 | LGKGGYGIVEK | 1 | Caenorhabditis elegans |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |